You searched for "vaginal"
Frequency-volume chart apps for nocturia: keeping urologists up at night
Background Nocturia is a bothersome symptom and the leading cause of disturbed sleep in adults. It is extremely common, with 55% of men and 60% of women aged 50 waking at least once in the night, with a further 20%...Innovations in urology – OOPE for trainees
“Innovation is the ability to see change as an opportunity – not a threat” – Steve Jobs [1] The world is changing rapidly. Healthcare has seen a fast reform, especially as a consequence of COVID-19. Urology is a rapidly evolving...Intravesical GAG replacement therapies for bladder pain syndrome / interstitial cystitis – an update
The barrier function of the glycosaminoglycan (GAG) layer of the urothelium was identified by Parsons in 1975, and intravesical therapies to treat chronic inflammatory conditions of the bladder were developed soon after. However, the active role of the urothelium in...Prostate cancer now England’s most common cancer
Prostate cancer cases overtook those of breast cancer by thousands in both 2022 and 2023, according to Prostate Cancer UK analysis of NHS data. Huge increase shows that more men than ever before are learning about their risk and taking...Post CCT fellowship in genitourethral reconstruction at St George’s Hospital: an experience unique to the UK
I first developed an interest in genitourethral reconstruction, particularly urethroplasty, at the beginning of my urology training. Working in Bristol and Weston Super Mare for David Dickerson inspired me to develop this further. Mr Dickerson performs one of the largest...
The future of bladder-sparing therapy is bright
Trimodal therapy (TMT), combining optimal transurethral resection of bladder tumour (TURBT) and concurrent chemoradiotherapy, has garnered significant attention for managing muscle-invasive bladder cancer (MIBC). This approach offers the potential for bladder preservation while delivering oncological outcomes comparable to radical cystectomy....Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...A research revolution
“The revolution is not an apple that falls when it is ripe. You have to make it fall.” Erenesto ‘Che’ Guevara There was a time, not so long ago, when you actually had to go to a library to read...Testicular tumour imaging
Testicular tumours are the most common tumour in young males with a peak incidence seen between 25 and 34 years [1]. The overall incidence is slowly increasing, although the exact reasons for this are uncertain, and there is a greater...Prostate cancer series: diagnostics 2
- Click here for Part 1 - A 68-year-old male was referred to the two-week wait prostatic clinic with a serum prostate specific antigen (PSA) of 17. He had no bothersome lower urinary tract symptoms, relevant past medical history or...
